![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CELLULAR AND MOLECULAR
Division of Cancer Prevention, Department of Medicine, State University of New York at Stony Brook, Stony Brook, New York (J.G., B.R.); and Department of Physiology and Pharmacology, City University of New York Medical School, New York, New York (K.K.)
NO-donating aspirin (NO-ASA) is a potentially important chemopreventive agent against cancer. Since positional isomerism affects strongly its potency in inhibiting colon cancer cell growth, we studied the metabolic transformations of its ortho-, meta-, and para-isomers in rat liver and colon cytosolic, microsomal, and mitochondrial fractions as well as in intact HT-29 human colon cancer cells. NO-ASA and metabolites were determined by high-performance liquid chromatography and products identified by mass spectroscopy, as required. For all three isomers, the acetyl group on the ASA moiety was hydrolyzed rapidly. This was followed by hydrolysis of the ester bond linking the salicylate anion to the spacer. The ortho- and para-isomers produced salicylic acid and a putative intermediate consisting of the remainder of the molecule, which via a rapid step generated nitrate, (hydroxymethyl)phenol, and a conjugate of spacer with glutathione. The meta-isomer, in contrast, generated salicylic acid and (nitroxymethyl)phenol, the latter leading to (hydroxymethyl)phenol and the glutathione-spacer conjugate. This metabolic pathway takes place in its entirety only in the cytosolic fraction of the tissues tested and in intact human colon cancer cells, perhaps reflecting exposure to the cytosolic glutathione S-transferase, which catalyzes the formation of the spacer-glutathione conjugate. Thus, the three positional isomers of NO-ASA differ in their metabolism and these differences correlate with their differential effects on cancer cell growth, underscoring the importance of positional isomerism in modulating drug effects.
Address correspondence to: Dr. Basil Rigas, Division of Cancer Prevention, Department of Medicine, SUNY at Stony Brook, Stony Brook, NY 11794-8160. E-mail: basil.rigas{at}sunysb.edu
This article has been cited by other articles:
![]() |
C. V. Rao, B. S. Reddy, V. E. Steele, C-X Wang, X. Liu, N. Ouyang, J. M.R. Patlolla, B. Simi, L. Kopelovich, and B. Rigas Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets. Mol. Cancer Ther., June 1, 2006; 5(6): 1530 - 1538. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Gao, K. Kashfi, X. Liu, and B. Rigas NO-donating aspirin induces phase II enzymes in vitro and in vivo Carcinogenesis, April 1, 2006; 27(4): 803 - 810. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Turchi Nitric oxide and cisplatin resistance: NO easy answers PNAS, March 21, 2006; 103(12): 4337 - 4338. [Full Text] [PDF] |
||||
![]() |
J. Gao, X. Liu, and B. Rigas Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress PNAS, November 22, 2005; 102(47): 17207 - 17212. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Goel, C. Gasche, and C. R. Boland Chemoprevention Goes Gourmet: Different Flavors of NO-Aspirin Mol. Interv., August 1, 2005; 5(4): 207 - 210. [Abstract] [Full Text] [PDF] |
||||